Peranan Immunoterapi Pada Kanker Paru
Abstract
Abstrak. Kanker paru masih menjadi masalah kesehatan secara menyeluruh, baik di dunia maupun di Indonesia, khususnya di Aceh. Saat ini kanker paru masih menjadi penyebab kematian tertinggi di dunia. Berbagai peneletian tentang tatalaksana kanker paru telah dikembangkan, perkembangan terapi kanker paru saat ini berupa immunoterapi yang menargetkan reseptor penghambat sel T, seperti program sel death (PD-1) , terapi checkpoint blockade, immunoterapi baru berdasarkan neoantigen selektif dengan tujuan pengobatan mampu mendorong sel yang di transformasikan.
Immunoterapi adalah salah satu metode pengobatan berbagai jenis tumor dengan efek samping yang dapat di atasi. Tujuan imunoterapi kanker adalah memberikan efektor antitumor (antibodi dan sel T ) terhadap pasien. Perkembangan ilmu pengetahuan tentang tatalaksana kanker berkembang sangat pesat, baik yang bersifat invasif maupun yang non invasif hingga penatalaksaan nano molekul. Tujuan pengobatan beruapa peningkatan kualitas hidup dan peningkatan survival rate.
Kata Kunci : kanker paru, immunoterapi, PD-1, PD-L1, checkpoint blockade
Abstract. Lung cancer is still a comprehensive health problem, both in the world and in Indonesia, especially in Aceh. Currently lung cancer is still the highest cause of death in the world. Various studies on the management of lung cancer have been developed, the development of lung cancer therapy currently in the form of immunotherapy that targets T cell receptor inhibitors, such as the cell death program (PD-1), checkpoint blockade therapy, new immunotherapy based on selective neoantigens with the aim of treatment being able to encourage cells that transformed.
Immunotherapy is one method of treating various types of tumors with side effects that can be overcome. The aim of cancer immunotherapy is to provide antitumor effectors (antibodies and T cells) to patients. The development of science about cancer management is developing very rapidly, both invasive and non-invasive to the management of nano molecules. Treatment goals include improving the quality of life and increasing survival rates.
Keyword: lung cancer, immunotherapy, PD-1, PD-L1, checkpoint blockade
Keywords
References
Daftar pustaka
Austin Huy Nguyen., Ilya G Berim. DKA. Cellular and Molecular Immunology of Lung. PMC. 2015;10(12):1711–30.
Yusuf A. Dasar-dasar Diagnosis Kanker Paru. Jakarta: Universitas Indonesia;2017.
Olive D. Recent Advances in Lung Cancer Immunotherapy : Input of T-Cell Epitopes Associated With Impaired Peptide Processing. 2019;10(July):1–8.
Peter J. Delves., Seamus J. Martin., Dennis R. Burton., Ivan M. Roitt. Roitt’s Essential Immunology. Thirteenth. London: Wiley Blackwell;2017.
Jr KFM, Jinushi M, Dranoff G. Immunosurveillance : Innate and Adaptive Antitumor Immunity. Second Edition. Cancer Immunotherapy: Immune Suppression and Tumor Growth. Elsevier;2013.101–113p.
Keshavarz-fathi M, Rezaei N. Chapter 1 - Cancer Immunology. Vaccines for Cancer Immunotherapy. Nima Rezaei and Mahsa Keshavarz-Fathi; 2019.1-17 p.
Cho JH. Immunotherapy for Non-small-cell Lung Cancer : Current Status and Future Obstacles. 2017;17(6):378–91.
Abdul K. Abbas., Andrew H. Lichtman. SP. Basic Immunology Functions and Disorders of The Immune System. fith editi. Canada: Elsevier; 2016.
Wang D, Gilbert J, Kim YJ, Surgery N. Immunotherapy : Who is Eligible ? 2018;50(4):867–74.
N.A. Rizvi, J. Mazières, D. Planchard, et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Onco.
Rizvi NA, Planchard D, Dy GK, Antonia SJ, Horn L, Minenza E, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. 2017;16(3):257–65.
Wang L, Zhao D, Qin K, Rehman FUL, Zhang X. Biomedicine & Pharmacotherapy E ff ect and biomarker of Nivolumab for non–small-cell lung cancer. Biomed Pharmacother. 2019;117(May):109199.
N.A. Rizvi, M.D. Hellmann, J.R. Brahmer, et al., Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non- Small-Cell Lung Cancer, J. Clin. Oncol. 34 (25)(2016)2969–2979.
Peters S, Kerr KM, Stahel R. PD-1 blockade in advanced NSCLC : A focus on pembrolizumab. Cancer Treat Rev. 2018;62:39–49.
Qin H, Wang F, Liu H, Zeng Z, Wang S, Pan X, et al. New advances in immunotherapy for non-small cell lung cancer. 2018;10(8):2234–45.
Raju S, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. 2018;63–75.
Memon H, Patel BM. Immune checkpoint inhibitors in non-small cell lung cancer : A bird â€TM s eye view. Life Sci. 2019;233(August):116713.
Li J, Liu M, Wang J, Liu Z, Xue J, Wang J, et al. Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer. 2011;1–5.
Rashdan S, Gerber DE. Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. 2019;8(5):202–7.
DOI: 10.24815/jks.v20i2.18499
Refbacks
- There are currently no refbacks.